Following a recent stock dip on a minor Q2 earnings miss, the bear case against Hims & Hers ($HIMS) has grown louder, with short-sellers claiming the company's entire weight-loss strategy is a ticking time bomb operating in a dangerous legal gray area. However, this narrative crumbles under scrutiny. In our new podcast episode, we dismantle this flawed argument by revealing how the bears are betting against a regulatory dream team, which includes former top executives from the FDA and Pfizer, and even the ex-CEO of Novo Nordisk on their board—professionals who would not risk their careers on a reckless scheme. Furthermore, the claim of dependency on one product is demonstrably false, as Hims is executing a diversified strategy that includes a booming $100 million oral weight-loss business and a proactive pivot to an FDA-approved generic GLP-1. While the shorts focus on short-term noise, they are completely missing the company's multi-year roadmap, which features game-changing catalysts like at-home lab testing and an AI-powered superapp.

Is Hims & Hers ($HIMS) the future of healthcare or a multi-billion-dollar house of cards? This episode dives into one of Wall Street's most exciting and controversial growth stories.

Hims & Hers built an empire by tackling the sensitive health issues people avoid talking about. By offering a simple telehealth platform for everything from hair loss to anxiety, they removed the stigma and inconvenience of the traditional doctor's office, rocketing to a projected $2.4 billion in revenue this year.

But their incredible success has attracted powerful enemies. In this episode, we cut through the noise to tell the story of their revolutionary mission and investigate the serious allegations from a prominent short-seller who claims the entire company is a fraud.

Tune in to understand the high-stakes battle over one of today's most disruptive companies.

Rocket Lab is a pioneering aerospace company revolutionizing access to space with its innovative small satellite launch services. Known for its Electron rocket, Rocket Lab offers frequent, cost-effective, and reliable launches, catering to the growing demand for satellite deployment in low Earth orbit. With a proven track record of successful missions, a robust launch cadence, and ambitious plans for reusable rocket technology and interplanetary missions, Rocket Lab is well-positioned in the rapidly expanding commercial space industry. Investing in Rocket Lab means backing a leader in the new space economy, driven by cutting-edge technology and a vision for a connected, data-driven future from orbit.